Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial
In a statement, Scholar Rock Holding Corporation (NASDAQ:SRRK) said the trial, which aims to assess its drug candidate apitegromab’s combination with tirzepatide, was generally well tolerated, leading...